Is a Large-Scale Screening for Alzheimer’s Disease Possible? Yes, in a Few Years
Recent evidence on blood-based biomarkers is pointing the way towards a new era of large-scale, feasible, cost-effective and non-invasive screening for Alzheimer’s disease (AD). This was one of the main focuses of the recent meeting of the European Union-North American Clinical Trials in AD (EU/US CTAD) Task Force, which took place in Barcelona in October 24–27, 2018, and convened drug and diagnostics developers from industry and academia in order to define a roadmap for the development and marketing of blood-based biomarkers (1).
According to the recent National Institute on Aging - Alzheimer’s Association (NIA-AA) and International Working Group (IWG-2) diagnostic criteria (2’4), AD biomarkers can be assessed using neuroimaging techniques (i.e. magnetic resonance, MR; and positron emission tomography, PET) and/or cerebrospinal fluid (CSF) collection, and include amyloid (PET or CSF), tau (PET or CSF) and neurodegeneration (MR, PET, or CSF). Among them, only MR is usually performed...
Conflict of interest: Dr. Ribaldi and Dr. Altomare have nothing to disclose. Dr. Frisoni reports grants from Alzheimer Forum Suisse, grants from Académie Suisse des Sciences Médicales (ASSM), grants from Avid Radiopharmaceuticals, grants from Biogen, grants from GE International, grants from Guerbert, grants from IFRAD Suisse (Association Suisse pour la Recherche sur l’Alzheimer), grants from Ixico, grants from Merz, grants from Nestlé, grants from Novartis, grants from Piramal, grants from Roche, grants from Siemens, grants from Teva Pharma, grants from Vifor Pharma, grants from Alzheimer’s Association, personal fees from AstraZeneca, personal fees from Avid Radiopharmaceuticals, personal fees from Elan, personal fees from GE International, personal fees from Lundbeck, personal fees from Pfizer, personal fees from Taurx, outside the submitted work.
- 1.Bateman RJ, Blennow K, Doody R, Hendrix S, Lovestone S, Salloway S, et al. Plasma Biomarkers of AD Emerging As Essential Tools For Drug Development: An EU/US CTAD Task Force Report. J Prev Alz Dis 2019;6(3):169–173Google Scholar
- 2.McKhann G, Knopman DS, Chertkow H, Hymann B, Jack CR, Kawas C, et al. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging- Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement. 2011;7(3):263–9.CrossRefGoogle Scholar
- 3.Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Vol. 7, Alzheimer’s and Dementia. 2011. p. 270–9.CrossRefGoogle Scholar
- 5.Verberk IMW, Slot RE, Verfaillie SCJ, Heijst H, Prins ND, van Berckel BNM, et al. Plasma Amyloid as Prescreener for the Earliest Alzheimer Pathological Changes. Ann Neurol. 2018Google Scholar
- 6.Nakamura A, Kaneko N, Villemagne VL, Kato T, Doecke J, Doré V, et al. High performance plasma amyloid-ß biomarkers for Alzheimer’s disease. Nature. 2018Google Scholar
- 7.Mattsson N, Cullen NC, Andreasson U, Zetterberg H, Blennow K. Association Between Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer Disease. JAMA Neurol. 2019;1–9.Google Scholar
- 8.Bos I, Vos S, Vandenberghe R, Scheltens P, Engelborghs S, Frisoni G, et al. The EMIF-AD Multimodal Biomarker Discovery study: Design, methods and cohort characteristics. Alzheimer’s Res Ther. 2018Google Scholar
- 9.Andrieu S, Guyonnet S, Coley N, Cantet C, Bonnefoy M, Bordes S, et al. Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial. Lancet Neurol. 2017;Google Scholar